AM-1638 is a full agonist of GPR40/FFA1 (EC50: 0.16 μM).

AM-1638 exhibits moderate cross-species plasma clearance and volume of distribution, resulting in plasma half-lives suitable for evaluation of its antidiabetic properties in mouse, rat, and cynomologus monkey. AM-1638 exhibits antidiabetic activity in BDF/DIO mice[1]. Moreover, oral administration of full agonist AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%).

1142214-62-7

C33H35FO4

514.63

DMSO:250 mg/mL (485.79 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years